Suppr超能文献

农村初级保健环境中心房颤动筛查、管理和指南推荐治疗:支持筛查各个阶段的电子健康工具的横断面研究和成本效益分析。

Atrial Fibrillation Screen, Management, and Guideline-Recommended Therapy in the Rural Primary Care Setting: A Cross-Sectional Study and Cost-Effectiveness Analysis of eHealth Tools to Support All Stages of Screening.

机构信息

Heart Research Institute Charles Perkins Centre University of Sydney Australia.

The George Institute for Global Health University of New South Wales Sydney Australia.

出版信息

J Am Heart Assoc. 2020 Sep 15;9(18):e017080. doi: 10.1161/JAHA.120.017080. Epub 2020 Aug 31.

Abstract

BACKGROUND Internationally, most atrial fibrillation (AF) management guidelines recommend opportunistic screening for AF in people ≥65 years of age and oral anticoagulant treatment for those at high stroke risk (CHA₂DS₂-VA≥2). However, gaps remain in screening and treatment. METHODS AND RESULTS General practitioners/nurses at practices in rural Australia (n=8) screened eligible patients (≥65 years of age without AF) using a smartphone ECG during practice visits. eHealth tools included electronic prompts, guideline-based electronic decision support, and regular data reports. Clinical audit tools extracted de-identified data. Results were compared with an earlier study in metropolitan practices (n=8) and nonrandomized control practices (n=69). Cost-effectiveness analysis compared population-based screening with no screening and included screening, treatment, and hospitalization costs for stroke and serious bleeding events. Patients (n=3103, 34%) were screened (mean age, 75.1±6.8 years; 47% men) and 36 (1.2%) new AF cases were confirmed (mean age, 77.0 years; 64% men; mean CHA₂DS₂-VA, 3.2). Oral anticoagulant treatment rates for patients with CHA₂DS₂-VA≥2 were 82% (screen detected) versus 74% (preexisting AF)(=NS), similar to metropolitan and nonrandomized control practices. The incremental cost-effectiveness ratio for population-based screening was AU$16 578 per quality-adjusted life year gained and AU$84 383 per stroke prevented compared with no screening. National implementation would prevent 147 strokes per year. Increasing the proportion screened to 75% would prevent 177 additional strokes per year. CONCLUSIONS An AF screening program in rural practices, supported by eHealth tools, screened 34% of eligible patients and was cost-effective. Oral anticoagulant treatment rates were relatively high at baseline, trending upward during the study. Increasing the proportion screened would prevent many more strokes with minimal incremental cost-effectiveness ratio change. eHealth tools, including data reports, may be a valuable addition to future programs. REGISTRATION URL: https://www.anzctr.org.au. Unique identifier: ACTRN12618000004268.

摘要

背景

在国际上,大多数房颤(AF)管理指南建议在≥65 岁的人群中进行机会性筛查,并对高卒中风险人群(CHA₂DS₂-VA≥2)进行口服抗凝治疗。然而,在筛查和治疗方面仍存在差距。

方法和结果

澳大利亚农村实践中的全科医生/护士(n=8)在就诊期间使用智能手机心电图对符合条件的患者(≥65 岁且无房颤)进行筛查。电子健康工具包括电子提示、基于指南的电子决策支持和定期数据报告。临床审核工具提取了去识别数据。结果与大都市实践(n=8)和非随机对照实践(n=69)的早期研究进行了比较。成本效益分析比较了基于人群的筛查与不筛查,并包括卒中和严重出血事件的筛查、治疗和住院费用。对 3103 名患者(34%)进行了筛查(平均年龄 75.1±6.8 岁;47%为男性),并确诊了 36 例(1.2%)新的房颤病例(平均年龄 77.0 岁;64%为男性;平均 CHA₂DS₂-VA 为 3.2)。CHA₂DS₂-VA≥2 的患者口服抗凝治疗率为 82%(筛查发现)与 74%(既往房颤)(=NS),与大都市和非随机对照实践相似。与不筛查相比,基于人群的筛查的增量成本效益比为每获得 1 个质量调整生命年增加 16578 澳元,每预防 1 例卒中增加 84383 澳元。全国实施每年可预防 147 例卒中。将筛查比例提高到 75%,每年可额外预防 177 例卒中。

结论

在农村实践中,一项由电子健康工具支持的房颤筛查计划筛查了 34%的合格患者,具有成本效益。在研究期间,口服抗凝治疗率基线较高,呈上升趋势。增加筛查比例将以最小的增量成本效益比变化预防更多的卒中。电子健康工具,包括数据报告,可能是未来计划的有价值的补充。

注册网址

https://www.anzctr.org.au。独特标识符:ACTRN12618000004268。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d90a/7726973/05c75305cbee/JAH3-9-e017080-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验